Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilona Hagelstein

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Frontiers in Immunology|March 30, 2026
Characterization of TROP-2 bispecific T cell engagers for immunotherapy of triple negative breast and bladder cancerCarlos Ávila-Nieto, Gundram Jung, Helmut R Salih, et al.
Journal of Ovarian Research|January 22, 2026
Targeting NKG2DLs with an ADCC enhanced fusion protein for induction of NK cell reactivity against ovarian cancerIlona Hagelstein, Kevin Wang, Annika Hölz, et al.
Frontiers in Immunology|February 7, 2024
An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancerMartina S Lutz, Kevin Wang, Gundram Jung, et al.
Frontiers in Immunology|May 20, 2024
The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomasSamuel J Holzmayer, Kai Liebel, Ilona Hagelstein, et al.
International Journal of Hematology|April 9, 2020
CD105 (endoglin) as risk marker in AML patients undergoing stem cell transplantationMelanie Märklin, Ilona Hagelstein, Clemens Hinterleitner, et al.
Frontiers in Immunology|August 18, 2025
Fc-optimized CD276 antibody enhances NK cell activation against non-small cell lung cancerSylwia A Stefańczyk, Xenija Kaiser, Ilona Hagelstein, et al.
Pathology Oncology Research : POR|August 29, 2025
B7-H3: a consistent marker in metastatic colorectal cancer with potential for targeted treatmentJulia M Ott, Verena Gassenmaier, Michael Bitzer, et al.
Leukemia & Lymphoma|June 17, 2020
Fc gamma receptor expression serves as prognostic and diagnostic factor in AMLJonas S Heitmann, Ilona Hagelstein, Clemens Hinterleitner, et al.
Frontiers in Immunology|October 24, 2022
B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcomaIlona Hagelstein, Monika Engel, Clemens Hinterleitner, et al.
Annals of Hematology|January 23, 2020
Identification of CD318 (CDCP1) as novel prognostic marker in AMLJonas S Heitmann, Ilona Hagelstein, Clemens Hinterleitner, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Frontiers in Immunology|March 30, 2026
Characterization of TROP-2 bispecific T cell engagers for immunotherapy of triple negative breast and bladder cancerCarlos Ávila-Nieto, Gundram Jung, Helmut R Salih, et al.
Journal of Ovarian Research|January 22, 2026
Targeting NKG2DLs with an ADCC enhanced fusion protein for induction of NK cell reactivity against ovarian cancerIlona Hagelstein, Kevin Wang, Annika Hölz, et al.
Frontiers in Immunology|February 7, 2024
An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancerMartina S Lutz, Kevin Wang, Gundram Jung, et al.
Frontiers in Immunology|May 20, 2024
The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomasSamuel J Holzmayer, Kai Liebel, Ilona Hagelstein, et al.
International Journal of Hematology|April 9, 2020
CD105 (endoglin) as risk marker in AML patients undergoing stem cell transplantationMelanie Märklin, Ilona Hagelstein, Clemens Hinterleitner, et al.
Frontiers in Immunology|August 18, 2025
Fc-optimized CD276 antibody enhances NK cell activation against non-small cell lung cancerSylwia A Stefańczyk, Xenija Kaiser, Ilona Hagelstein, et al.
Pathology Oncology Research : POR|August 29, 2025
B7-H3: a consistent marker in metastatic colorectal cancer with potential for targeted treatmentJulia M Ott, Verena Gassenmaier, Michael Bitzer, et al.
Leukemia & Lymphoma|June 17, 2020
Fc gamma receptor expression serves as prognostic and diagnostic factor in AMLJonas S Heitmann, Ilona Hagelstein, Clemens Hinterleitner, et al.
Frontiers in Immunology|October 24, 2022
B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcomaIlona Hagelstein, Monika Engel, Clemens Hinterleitner, et al.
Annals of Hematology|January 23, 2020
Identification of CD318 (CDCP1) as novel prognostic marker in AMLJonas S Heitmann, Ilona Hagelstein, Clemens Hinterleitner, et al.
Pageof 3